This report provides comprehensive information on the current therapeutic developmental pipeline of Enzo Biochem
is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France.
Additionally, Sirona Biochem
contrives to make an anti-aging skin care treatment that merges their patented cell preservation glycoprotein with Cincinnati Children's technology.
has a compound in development that has the potential to achieve substantial shareholder value.
As part of the deal, R&D Systems, which develops purified cytokines (proteins), antibodies and assay kits, has also taken over UK Boston Biochem
Limited, a distributor of Boston Biochem
exclusively licensed the three patents (US Patent Nos.
Pharma developed the world's leading Aids drugs, the latest of which is called Trizivir.
On December 11, 2000, Shire and BioChem
announced they had entered into an agreement to merge the two groups to form a leading global specialty pharma company.
Pharma currently has meningococcal vaccine in the first phase of clinical trials.
says lamivudine has been filed for approval in more than 30 countries and has already been approved in the Philippines, New Zealand, Pakistan and Canada.
is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.
Going Global Innovation is an excellent initiative that promotes international R&D collaborations and we are very pleased to have been awarded this funding, commented Sirona Biochem
Chief Executive Officer, Neil Belenkie.
stated, "Enzo is pleased to have settled with Sigma-Aldrich on favorable terms.
Wasting response in humans as well as several forms of debilitating inflammation, among other side effects afflicting recipients of bone marrow transplantation may be significantly alleviated using a new treatment developed by scientists at Hadassah University Hospital and Enzo Biochem
This decision is in line with the European Patent Office Opposition Division's recent decisions dismissing Emory oppositions against BioChem
Pharma's pioneering patents covering compositions of matter for a wide range of nucleoside analogues (European Patent 337 713) and 3TC (European Patent 382 526).